NASDAQ: ATXSAstria Therapeutics Inc Stock
$4.11+0.07 (+1.73%)
Updated Apr 21, 2025
ATXS Price
$4.11
Fair Value Price
$0.96
Market Cap
$231.94M
52 Week Low
$3.56
52 Week High
$12.92
P/E
-2.45x
P/B
0.73x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$94.26M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.07
Operating Cash Flow
-$81M
Beta
0.93
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ATXS Overview
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ATXS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ATXS
Ranked#366 of 462
Ranked#366 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important ATXS news, forecast changes, insider trades & much more!
ATXS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ATXS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATXS ($4.11) is overvalued by 326.23% relative to our estimate of its Fair Value price of $0.96 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ATXS ($4.11) is not significantly undervalued (326.23%) relative to our estimate of its Fair Value price of $0.96 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ATXS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ATXS due diligence checks available for Premium users.
Valuation
ATXS fair value
Fair Value of ATXS stock based on Discounted Cash Flow (DCF)
Price
$4.11
Fair Value
$0.96
Overvalued by
326.23%
ATXS ($4.11) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ATXS ($4.11) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ATXS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ATXS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.45x
Industry
-184.27x
Market
27.14x
ATXS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.73x
Industry
4.04x
ATXS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ATXS's financial health
Profit margin
Revenue
$0.0
Net Income
-$25.6M
Profit Margin
0%
ATXS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$342.4M
Liabilities
$23.1M
Debt to equity
0.07
ATXS's short-term assets ($334.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATXS's short-term assets ($334.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATXS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATXS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$17.4M
Investing
-$3.7M
Financing
$0.0
ATXS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ATXS vs Biotech Stocks
Astria Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.